Adaptation of lenvatinib treatment in patients with hepatocellular carcinoma and portal vein tumor thrombosis
ConclusionLenvatinib treatment should be avoided in patients with Vp4 with a high degree of portal trunk occlusion because of concerns about decreased portal blood flow.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Children | CT Scan | Drugs & Pharmacology | Hepatocellular Carcinoma | Liver Cancer | Study | Thrombosis